title: Prolonged treatment with finasteride (a 5 alpha-reductase inhibitor) does not affect bone density and metabolism.
abstract: OBJECTIVE
  Since it is not clear whether testosterone or dihydrotestosterone is the active hormone in bone metabolism, we wished to assess the effect of finasteride, a 5 alpha-reductase inhibitor, or vertebral bone mineral density and parameters of bone and mineral metabolism.
  
  
  METHODS
  Patients were treated in a randomized, double-blind controlled study with either placebo, 1 or 5 mg/day finasteride.
  
  
  METHODS
  Twenty-three men with benign prostatic hyperplasia (BPH) were included in this study; eight received placebo, seven were allocated to treatment with 1 mg/day, and eight to 5 mg/day finasteride for 12 months.
  
  
  METHODS
  Vertebral bone mineral density was measured at the lumbar spine by dual energy X-ray bone densitometry. Serum calcium, phosphorus, parathyroid hormone, osteocalcin and vitamin D metabolites were measured regularly. Urinary calcium and creatinine excretion were monitored as well.
  
  
  RESULTS
  Finasteride caused a significant decrease in serum dihydrotestosterone after 6 and 12 months, but no effect on serum testosterone. Vertebral bone mineral density remained unaltered. None of the other parameters monitored were affected except for a small unexplained increase in 1.25-dihydroxyvitamin D in the group receiving 5 mg finasteride/day.
  
  
  CONCLUSIONS
  Testosterone is probably the active hormone in bone metabolism. However, oestradiol, the product of testosterone aromatization (which remains unaltered under finasteride) may yet be another possible responsible steroid in the maintenance of bone density. We can also not rule out that the small amount of dihydrotestosterone remaining under finasteride administration is sufficient for maintaining normal bone metabolism.
mesh_terms: D058891:5-alpha Reductase Inhibitors; D015502:Absorptiometry, Photon; D000368:Aged; D000736:Androstenes / Q000627:therapeutic use*; D001378:Azasteroids / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects / Q000502:physiology*; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism*; D002117:Calcitriol / Q000097:blood; D002118:Calcium / Q000378:metabolism; D013196:Dihydrotestosterone / Q000097:blood; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D018120:Finasteride; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000097:blood / Q000188:drug therapy*
chemical_list: D058891:5-alpha Reductase Inhibitors; D000736:Androstenes; D001378:Azasteroids; D013196:Dihydrotestosterone; D018120:Finasteride; D002117:Calcitriol; D002118:Calcium